henatinib
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2010 (NCT01416623)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2- Mol. weight
- 468.53 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545416 ↗
- ChEMBLCHEMBL1277072 ↗
Also known as
- 2-((5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-5-(2-hydroxy-3-morpholinopropyl)-3-methyl-5,6,7,8-tetrahydro-1h-pyrrolo(3,2-c)azepin-4-ketone
- henatinib
- henatinib
- henatinib
- henatinib
- henatinib
- henatinib maleate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01416623 | Phase 1 | Sep 1, 2010 | Fudan University, Hengrui Therapeutics, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Hengrui Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2010 |
2 organizations
Page 1 / 1